Biotie, Seikagaku end licensing deal for VAP-1 antibody program

04/25/2012 | Genetic Engineering & Biotechnology News

Biotie Therapies regained the development and commercialization rights in the Asia-Pacific region for BTT-1023, its VAP-1 antibody program, after agreeing to terminating a licensing deal with Seikagaku. The reprofiling of BTT-1023 to target fibrotic diseases no longer fits Seikagaku's business strategy, Biotie CEO Timo Veromaa said. Biotie anticipates initiating proof-of-concept clinical trials this year.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Assistant General Counsel, Regulatory
Cardinal Health
Waukegan, IL
Santa Ana, CA
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Sr Manager, Business Conduct
Gilead Sciences
Foster City, CA
Chief Executive Officer
UCare Minnesota
Minneapolis, MN